2023 International Congress » Huntington's Disease

24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)

S. Gray, M. Lewis, T. Kazdoba, A. Koenig, E. Lefler, K. Paumier, M. Quirk, J. Doherty (Cambridge, USA)

A case of trichotillomania as the preceding symptom of Huntington’ s diseaseand the effect of risperidone

Y. Degirmenci, N. Bicak (Istanbul, Turkey)

A family of Huntington’s disease with genetic anticipation in its paternal inheritance

KY. Park, S. Jo, S. Lee, J. Lee, SJ. Chung (Daejeon, Republic of Korea)

A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease

E. Furr Stimming, D. Claassen, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years

L. Van_der Bent, C. Brouwers, A. Stam, L. Spronck, J. Klíma, J. Juhásová, B. Levinská, S. Juhás, J. Motlík, M. Evers, Z. Ellederova, A. Valles (Amsterdam, Netherlands)

Apathy and impulsivity co-occur in Huntington’s disease

L. Morris, K. Horne, L. Paermentier, C. Buchanan, M. Macaskill, D. Myall, M. Husain, R. Roxburgh, T. Anderson, C. Le Heron (Christchurch, New Zealand)

Case Study: Pitfalls of Commercial Genetic Testing for Huntington’s Disease

L. Fanty, J. Bravo, S. Corrigan, M. Maczis, L. Kugelmann, A. Wagle Shukla, M. Farrer, N. Mcfarland (Gainesville, USA)

Cervical dystonia with early onset as initial manifestation of adult-onset Huntington’s disease

I. šarac, H. šarac, F. Borovečki, N. Božina, J. Sertić, I. Ivek, L. Bagarić Krakan, Z. Krešić (Zagreb, Croatia)

Characteristics of Huntington disease in a north Indian cohort

D. Radhakrishnan, J. George, M. Faruq, R. Rajan, K. Kanojia, E. Arunmozhimaran, A. Das, A. Agarwal, A. Pandit, A. Srivastava (New Delhi, India)

Characterization of social cognition impairment in Huntington‘s disease

YF. Cheng, KC. Liu, TM. Yang, Y. Xiao, QR. Jiang, JX. Huang, SR. Zhang, XJ. Gu, JM. Burgunder, HF. Shang (Chengdu, China)

Chorea improvements over time with once-daily valbenazine treatment in adults with Huntington disease

E. Furr Stimming, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

Clinical and molecular features of Tunisian patients with Biallelic mutations in Huntington’s Disease

H. Nehdi, F. Nabli, Z. Saied, S. Ben Sassi, R. Amouri (Tunis, Tunisia)

Clinical correlates of olfactory dysfunction in Huntington’s disease

N. Rocha, J. Patino, S. Abdollah Zadegan, H. Coco, A. Liang, F. Ramirez, E. Furr Stimming (Houston, USA)

Cortical Control of Gait and Balance During Single and Dual Tasks in Huntington’s Disease: an fNIRS study

J. O'Keefe, N. Purcell, S. Stuart, R. Vitorio, B. Ouyang, D. Hall (Chicago, USA)

Discriminative properties and sensitivity to change of three cognitive assessment instruments in Huntington’s disease

A. Horta-Barba, S. Martinez-Horta, J. Pérez-Pérez, A. Puig-Davi, N. de Lucia, G. de Michele, E. Salvatore, S. Kehrer, J. Priller, S. Migliore, F. Squitieri, A. Castaldo, C. Mariotti, V. Mañanes, J. Lopez-Sendon, N. Rodriguez, A. Martinez-Descals, F. Júlio, C. Januário, M. Delussi, M. de Tommaso, S. Noguera, J. Ruiz-Idiago, E. J. Sitek, R. Wallner, A. Nuzzi, J. Pagonabarraga, J. Kulisevsky, HD. Disease Network (BARCELONA, Spain)

Education level and the onset and severity of symptoms in Huntington’s disease

SR. Zhang, YF. Cheng, XJ. Gu, KC. Liu, JY. Lin, TM. Yang, Y. Xiao, QR. Jiang, JX. Huang, QQ. Wei, RW. Ou, YB. Hou, LY. Zhang, CY. Li, JM. Burgunder, HF. Shang (Chengdu, China)

Effectiveness of deep brain stimulation in the treatment of Huntington’s disease

H. Rodrigues, G. Mantovani, M. da Rosa, V. de Souza, L. Aires, M. Fin, L. Lobato, R. Albuquerque, PL. da Silva, A. Hilbig (Porto Alegre, Brazil)

Effects of a small molecule angiotensin IV analog on Huntington’s disease animal model

R. Wells, A. Azzam, A. Hiller, M. Sardinia (Portland, USA)

Effects of cerebellar cTBS on motor symptoms in Huntington’s disease: a feasibility and pilot study

JF. Martin Rodriguez, M. Gomez Crespo, FJ. Gómez Campos, AM. Castellano-Gerrero, V. Villarreal, FJ. Palomar Simón, P. Porcacchia, F. Carrillo, S. Jesús, P. Mir (Sevilla, Spain)

Emerging treatments targeting DNA and RNA in Huntington’s disease: a review of future perspectives and current challenges

G. Lima, F. Sarmento, I. Camargo, R. Saba, S. Silva, V. Borges, H. Ferraz (São Paulo, Brazil)

Epidemiological analysis of autosomal dominant chorea in Eastern Algeria

Y. Mecheri, D. Satta, F. Serradj (Constantine, Algeria)

Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington’s disease

E. Furr Stimming, S. Abdollah Zadegan, J. Patino, N. Rocha (Houston, USA)

Feeding dystonia revealing Huntington’s disease, about a case

CH. Boukadir, S. Ouardi, N. Zemmouchi, N. Kassouri, W. Amer Elkhedoud (Ben Aknoun, Algiers, Algeria)

Gemini digital twins identified neuro-common and disease-specific drivers of rate of change in NfL in Huntington’s disease, Parkinson disease and Alzheimer disease

X. Shen, S. Sathe, L. Sun, P. Ashrap, K. Johnson, S. Sukhram, S. Reddy, S. Shin, J. Latourelle, C. Sampaio (Somerville, USA)

Hazard ratios of suicidality in a large Huntington disease population compared with controls: marginal structural modeling of Enroll-HD registry data

S. Reshef, V. Sung, G. Smith, O. Harari, D. Zhang, M. Forrest Gordon, R. Willock, R. Ribalov, J. Robles-Zurita, E. Furr Stimming (Parsippany-Troy Hills, USA)

Huntington’s disease in Senegal Epidemiological and clinical aspects

M. Fall (Dakar, Senegal)

Huntington’s disease patients with intermediate allele in Tunisia

H. Nehdi, Z. Saied, F. Nabli, S. Ben Sassi, R. Amouri (Tunis, Tunisia)

Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease

R. Mehanna, E. Furr Stimming, D. Haubenberger, O. Klepitskaya, S. Aggarwal, S. Kumar, O. Topaloglu, J. Goldstein, E. Kayson, M. Serbin (Houston, USA)

Levodopa-induced dyskinesia and Huntington’s chorea: link to current motor control theories

JF. Daneault, Y. Liu, J. Miranda, C. Duval, M. Chen, S. Lee (Newark, USA)

Localisation of distinct brain networks in premanifest and manifest Huntington’s disease

E. Younger, E. Ellis, J. Joutsa, D. Corp (Burwood, Australia)

Longitudinal imaging of regional volumes, presynaptic terminals and glucose metabolism in brains of people with early Huntington’s disease

A. Delva, K. van Laere, W. Vandenberghe (Leuven, Belgium)

Melatonin for huntington disease (HD) gene carriers with HD-related sleep disturbance – a pilot study

J. Patino, S. Zadegan, N. Rocha, N. Karagas, W. Tanigaki, B. Duncan, E. Furr Stimming (Houston, USA)

Modifying clinical and electrophysiological parameters through Transcranial pulsed current stimulation (tPCS) in Huntington disease

M. Tuesta Bernaola, J. Ganguly, A. Parra Peña, M. Jog (London, Canada)

Neurologic music therapy for fine motor rehabilitation in Huntington’s disease: a pilot study

E. Forbes, L. Lattanzio, L. Quiller, L. Seeberger, I. Buard (Aurora, USA)

Pilot study of outpatient rehabilitation of patients with Huntington’s disease in Russia

E. Lysogorskaia, T. Ivanov, M. Gukovskaya, A. Mendalieva, L. Brylev (Moscow, Russian Federation)

Racial and Ethnic Differences in Suicidal Ideation in North American patients with Huntington’s Disease: Analysis using the ENROLL-HD Dataset

A. Mendizabal, Y. Bordelon, S. Perlman (Los Angeles, USA)

Real-world effectiveness and safety of deutetrabenazine in patients with chorea associated with Huntington disease

V. Sung, A. White, H. Romdhani, D. Goldschmidt, R. Ayyagari, N. Chaijale, A. Yaari, M. Gordon, J. Logan, A. Yang, R. Ribalov (Birmingham, USA)

Regional brain volume and cognitive alterations in Huntington’s Disease Patients

M. Garon, L. Weis, L. Lerjefors, F. Pistonesi, V. Cianci, N. Cazzola, ML. Nasi, G. Bonato, D. Cecchin, M. Carecchio, A. Antonini, R. Biundo (padova, Italy)

Self-report vs. informant-report of problematic behaviors using the Huntington’s Disease-Behavioral Questionnaire

S. Hughes, E. Churchill, G. Parkin, B. Culbert, A. Smirnova, A. Hall, P. Gilbert, J. Corey-Bloom (San Diego, USA)

Study protocol for the iMarkHD study in individuals with Huntington’s disease

D. van Wamelen, T. Wood, M. Veronese, C. Ginestet, N. Martin, O. Makos, J. Badenoch, M. Hartmann, A. Rangel Cristales, E. Rabiner, R. Gunn, S. Tabrizi, A. Wood, S. Williams (London, United Kingdom)

Telemedicine and in-person encounters in a Huntington’s disease cohort: virtually the same

E. Girouard, JF. Daneault, A. James-Palmer, S. Chouinard, A. Richard (Montréal, Canada)

The Blood-Brain Barrier Integrity and Prevalence of Intrathecal T Helper 17.1 Cells in Huntington´s Disease

B. ásbjörnsdóttir, C. Musaeus, M. Hellem, T. Vinther-Jensen, L. Hjermind, A. Simonsen, M. von Essen, F. Sellebjerg, J. Nielsen (Copenhagen, Denmark)

The role of the default mode network and striatal circuits in the expression of depressive symptoms in premanifest Huntington’s disease

T. Barta, L. Novelli, N. Georgiou-Karistianis, J. Stout, S. Loi, Y. Glikmann-Johnston, A. Razi (Clayton, Australia)

Transition among HD-ISS stages as an endpoint in clinical trials for HD

J. Mills, J. Long, J. Vaidya, S. Sathe, C. Sampaio, S. Tabrizi (Iowa City, USA)

Understanding caffeine consumption in Huntington’s Disease

J. Adrissi, S. Brooker, A. Mcbride, D. Larson, E. Gausche, D. Bega (Los Angeles, USA)